Skip to main content

Table 2 Correlation between ERα-36 expression and clinico-pathological features

From: ERα-36 regulates progesterone receptor activity in breast cancer

VariableERα-36 low, no. (%)ERα-36 high, no. (%)p value
Age (years)Mean (+ SD)56.6 (+ 12.3)57.9 (+ 12.9)0,43
Age groups< 50 years32 (33.7%)19 (29.2%)0.5
> 50 years63 (66.3%)46 (70.8%) 
SideRight42 (44.2%)30 (46.2%)0.8
Left53 (55.8%)35 (53.8%) 
T. size< 2 cm41 (43.2%)27 (41.5%)0.83
> 2 cm54 (56.8%)38 (58.5%) 
LN metNegative45 (47.4%)31 (47.4%)0.9
Positive50 (52.6%)34 (52.3%) 
SBR gradeGr 113 (13.7%)13 (20%)0.039††
Gr 250 (52.6%)21 (32.3%) 
Gr 332 (33.7%)31 (47.7%) 
ERα statusNegative9 (9.6%)5 (7.7%)0.7††
Positive85 (90.4%)60 (92.3%) 
PR statusNegative23 (24.5%)17 (26.6%)0.7
Positive71 (75.5%)47 (73.4%) 
ERα/PR detailedERα+/PR+71 (75.5%)47 (73.4%)0.78††
ERα+/PR−14 (14.9%)12 (18.8%) 
ERα−/PR+0 (0.0%)0 (0.0%) 
ERα−/PR−9 (9.6%)5 (7.8%) 
Her 2 statusNegative78 (85.7%)51 (83.6%)0.7
Over-expressed13 (14.3%)10 (16.4%) 
  1. Tam tamoxifen, AI aromatase inhibitor, Anthra anthracycline
  2. *Correlations tested using Pearson’s chi-square test (2 sided) unless otherwise specified
  3. Difference between means using the Student t test
  4. ††Fisher’s exact test